TipRanks
Advertisement
Advertisement

ALKS Stock Latest News

Workday downgraded, Fox Corp. upgraded: Wall Street’s top analyst calls
The FlyWorkday downgraded, Fox Corp. upgraded: Wall Street’s top analyst calls
5d ago
EAT
EFX
Alkermes reinstated with a Buy at Truist
PremiumThe Fly
Alkermes reinstated with a Buy at Truist
5d ago
ALKS
Alkermes to present new data on alixorexton, LUMRYZ
PremiumThe Fly
Alkermes to present new data on alixorexton, LUMRYZ
8d ago
ALKS
Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study
PremiumCompany Announcements
Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study
14d ago
ALKS
Alkermes resumed with a Neutral at Goldman Sachs
PremiumThe Fly
Alkermes resumed with a Neutral at Goldman Sachs
27d ago
ALKS
Alkermes price target raised to $61 from $58 at Baird
PremiumThe FlyAlkermes price target raised to $61 from $58 at Baird
29d ago
ALKS
Alkermes ADHD Data Seen as Inconclusive; Gerberry Maintains Sell Rating and Unchanged $38 Price Target
Premium
Ratings
Alkermes ADHD Data Seen as Inconclusive; Gerberry Maintains Sell Rating and Unchanged $38 Price Target
29d ago
ALKS
Alkermes: Orexin Franchise Proof-of-Concept Supports Balanced Risk-Reward; Hold Rating Reiterated with Unchanged $43 Price Target
Premium
Ratings
Alkermes: Orexin Franchise Proof-of-Concept Supports Balanced Risk-Reward; Hold Rating Reiterated with Unchanged $43 Price Target
30d ago
ALKS
Alkermes data show measurable improvements in ADHD, says H.C. Wainwright
PremiumThe Fly
Alkermes data show measurable improvements in ADHD, says H.C. Wainwright
30d ago
ALKS
Alkermes: Orexin Agonism in ADHD Shows Early Promise; Buy Rating Reiterated with Unchanged $62 Price Target
PremiumRatings
Alkermes: Orexin Agonism in ADHD Shows Early Promise; Buy Rating Reiterated with Unchanged $62 Price Target
30d ago
ALKS
Morning Movers: Crypto stocks rise as bitcoin hits highest level since January
PremiumThe Fly
Morning Movers: Crypto stocks rise as bitcoin hits highest level since January
30d ago
ACN
HPQ
Alkermes jumps 8% to $46.99 after Phase I adult ADHD data
PremiumThe Fly
Alkermes jumps 8% to $46.99 after Phase I adult ADHD data
30d ago
ALKS
Alkermes Reports Positive Phase 1 ADHD Study Results
PremiumCompany AnnouncementsAlkermes Reports Positive Phase 1 ADHD Study Results
30d ago
8K
ALKS
Alkermes announces Phase 1b results of ALKS 7290 in ADHD
Premium
The Fly
Alkermes announces Phase 1b results of ALKS 7290 in ADHD
30d ago
ALKS
Alkermes Strengthens Board with New Director Appointment
Premium
Company Announcements
Alkermes Strengthens Board with New Director Appointment
1M ago
8K
ALKS
Alkermes announces appointment of Whitaker to Board of Directors
PremiumThe Fly
Alkermes announces appointment of Whitaker to Board of Directors
1M ago
ALKS
Mizuho survey shows no consensus into Alkermes ADHD data
PremiumThe Fly
Mizuho survey shows no consensus into Alkermes ADHD data
2M ago
ALKS
Trump Trade: U.S. considering new semiconductor tariffs
PremiumThe Fly
Trump Trade: U.S. considering new semiconductor tariffs
2M ago
MU
AMD
White House to announce drug pricing deals with biotechs, Bloomberg reports
PremiumThe Fly
White House to announce drug pricing deals with biotechs, Bloomberg reports
2M ago
ALKS
ALNY
Alkermes’ alixorexton featured in published Phase 2 study of narcolepsy
PremiumThe FlyAlkermes’ alixorexton featured in published Phase 2 study of narcolepsy
2M ago
ALKS
Alkermes Amends Credit Agreement to Lower Borrowing Costs
Premium
Company Announcements
Alkermes Amends Credit Agreement to Lower Borrowing Costs
2M ago
8K
ALKS
Alkermes Earnings Call Highlights Orexin-Fueled Growth
Premium
Company Announcements
Alkermes Earnings Call Highlights Orexin-Fueled Growth
3M ago
ALKS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >